treating multiple sclerosis. Hauser noted that the study results are “extremely exciting, both in terms of the prospect of improved therapy for people with multiple sclerosis but also for the lessons that it teaches us about the fundamental cause of the disease.”
The new study evaluated ocrelizumab in 220 individuals with multiple sclerosis who were divided into four groups: two received injections of the experimental drug at two different doses, one received the standard multiple sclerosis drug interferon-beta, and one was given a placebo.
Using magnetic resonance imaging (MRI), the investigators followed the progression of the treatment by evaluating the number of lesions observed in the brain scans and the severity and frequency of the symptoms. Overall, the patients